Basiliximab
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Basiliximab |
| DrugBank ID | DB00074 |
| Brand Names (EU) | Simulect |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 95.61% |
Approved Indication (EMA)
Simulect is indicated for the prophylaxis of acute organ rejection in de-novo allogeneic renal transplantation in adult and paediatric patients (1-17 years). It is to be used concomitantly with ciclosporin for microemulsion- and corticosteroid-based immunosuppression, in patients with panel reactive antibodies less than 80%, or in a triple maintenance immunosuppressive regimen containing ciclosporin for microemulsion, corticosteroids and either azathioprine or mycophenolate mofetil.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | plasma cell myeloma | 95.61% | DL |
| 2 | bronchitis | 95.54% | DL |
| 3 | indolent plasma cell myeloma | 95.29% | DL |
| 4 | hemoglobinopathy | 94.28% | DL |
| 5 | gastric carcinoma | 93.89% | DL |
| 6 | diffuse gastric adenocarcinoma | 93.75% | DL |
| 7 | partial deletion of the short arm of chromosome 16 | 93.52% | DL |
| 8 | beta-thalassemia with other manifestations | 93.29% | DL |
| 9 | hemolytic anemia due to glucophosphate isomerase deficiency | 92.93% | DL |
| 10 | Jeune syndrome situs inversus | 92.86% | DL |
| 11 | orofacial clefting syndrome | 92.81% | DL |
| 12 | gastric linitis plastica | 92.74% | DL |
| 13 | interventricular septum aneurysm | 92.72% | DL |
| 14 | pyruvate kinase deficiency of red cells | 92.70% | DL |
| 15 | Pierre Robin syndrome associated with a chromosomal anomaly | 92.68% | DL |
| 16 | pulmonary valve disease | 92.62% | DL |
| 17 | partial deletion of the long arm of chromosome 7 | 92.60% | DL |
| 18 | disorder of fucoglycosan synthesis | 92.60% | DL |
| 19 | partial deletion of the long arm of chromosome 22 | 92.56% | DL |
| 20 | genetic syndromic Pierre Robin syndrome | 92.56% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.